Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics Inc. (LUCD)
:LUCD
LUCD Stock Chart & Stats
$1.25
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.25
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.75 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)651.54K
Market Cap
$146.83M
Enterprise Value$140.53M
Total Cash (Recent Filing)$47.33M
Total Debt (Recent Filing)$24.34M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Mar 30, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding131,098,750
10 Day Avg. Volume717,266
30 Day Avg. Volume651,543
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)7.67
Price to Sales (P/S)9.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue0.12
Enterprise Value/Gross Profit-0.29
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$4.05Price Target Upside224.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$4.62M
Bulls Say, Bears Say
Bulls Say
Financial StabilityStable cash burn and a cash balance of approximately $47M provide financial stability for LUCD.
Market OpportunityThe estimated addressable domestic market opportunity for EsoGuard is ~$2 billion based on tens of millions of U.S. patients with gastroesophageal reflux disease (GERD).
Medicare CoverageLUCD is one step closer to receiving Medicare coverage for EsoGuard, which gives confidence in revenue estimates.
Bears Say
Financial PerformanceThe company reported 3Q25 results that were below the analyst's estimate and FactSet consensus.
Free Cash FlowLucid burned $10.9 million in free cash flow in 3Q25, which is higher than the analyst's estimate of $6.6 million.
Revenue ConcernsLUCD missed consensus revenue, which could concern investors about the company's financial performance.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.75 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $146.83M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
Lucid Diagnostics Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 99 days.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Lucid Diagnostics Inc. released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.095 by -$0.005.
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate is -0.09.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 131,098,750 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Lucid Diagnostics Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.095. Following the earnings report the stock price went up 6.731%.
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.05 (224.00% Upside)
$4.05 (224.00% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $101.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.03%
12-Months-Change
Fundamentals
Return on Equity
-331.24%
Trailing 12-Months
Asset Growth
135.41%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics (LUCD) is a medical diagnostics company focused on developing and commercializing innovative solutions for the early detection and prevention of gastrointestinal diseases, particularly esophageal cancer. The company operates primarily in the healthcare sector, leveraging its proprietary technology to provide non-invasive diagnostic tests that aid physicians in identifying precancerous conditions. Its core product, the EsoGuard test, is designed to analyze cells from the esophagus to detect early signs of cancer and other related disorders, facilitating timely intervention and improving patient outcomes.
LUCD Company Deck
LUCD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic achievements, including strengthening the market access team and positive progress towards Medicare coverage, which are expected to drive future growth. However, the company faced flat revenue growth and ongoing reimbursement challenges, impacting short-term financial performance.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$4.05
▲(224.00% Upside)
Technical Analysis
Ownership Overview
2.40% Insiders
4.22% Mutual Funds
12.50% Other Institutional Investors
76.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---